Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-DOTATOC
- Development stage
- Unknown
- Lead developer
- Advanced Accelerator Applications
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
177Lu-DOTATOC is a radiopharmaceutical and peptide receptor radionuclide therapy (PRRT) agent being developed by Excel Diagnostics and Nuclear Oncology Center (EDNOC) for the treatment of non-gastroenteropancreatic neuroendocrine tumors (non-GEP-NETs). It consists of the radionuclide lutetium-177 conjugated to DOTATOC (edotreotide), a somatostatin analog peptide. The drug targets the somatostatin receptor (SSTR), which is frequently overexpressed on the surface of neuroendocrine tumor cells. Upon binding to the receptor, the complex is internalized, allowing the lutetium-177 isotope to emit beta radiation that causes targeted DNA damage and cell death in the tumor. It is currently being investigated in a Phase II clinical trial for patients with SSTR-positive pulmonary neuroendocrine tumors, pheochromocytoma, paraganglioma, thymic neuroendocrine tumors, and neuroendocrine tumors of unknown primary.
- Brand names
- Solucin
- Other names
- lutetium Lu 177 edotreotide177Lu-DOTA-Tyr3-octreotidelutetium (177Lu) edotreotide
02
Targets
SSTR5 (Somatostatin receptor 5)SSTR3 (Somatostatin receptor 3)SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on 177Lu-DOTATOC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-DOTATOC.